References

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2016-15-2-101-106

oncotomsk-339

Research Article

ОБЗОРЫ

REVIEWS

РАДИОИММУНОТЕРАПИЯ В ЛЕЧЕНИИ ЗЛОКАЧЕСТВЕННЫХ ОБРАЗОВАНИЙ

RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES

Чернов

В. И.

Chernov

V. I.

доктор медицинских наук, профессор, заместитель директора по научной работе и инновационной деятельности, руководитель отделения радионуклидной диагностики, Томский НИИ онкологии (г. Томск, Российская Федерация). SPIN-код: 6301-3612.

MD, DSc, Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 6301-3612.

chernov@oncology.tomsk.ru

Брагина

О. Д.

Bragina

O. D.

кандидат медицинских наук, научный сотрудник, Национальный исследовательский Томский политехнический университет (г. Томск, Российская Федерация). SPIN-код: 7961-5918.

MD, PhD, Researcher, National Research Polytechnic University (Tomsk, Russian Federation). SPIN-code: 7961-5918.

rungis@mail.ru

Синилкин

И. Г.

Sinilkin

I. G.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, Томский НИИ онкологии (г. Томск, Российская Федерация). SPIN-код: 7254-3474.

MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 7254-3474.

sinilkinig@oncology.tomsk.ru

Тицкая

А. А.

Titskaya

A. A.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, Томский НИИ онкологии (г. Томск, Российская Федерация). SPIN-код: 9110-1730.

MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 9110-1730.

tickayaaa@oncology.tomsk.ru

Зельчан

Р. В.

Zelchan

R. V.

кандидат медицинских наук, врач-радиолог отделения радионуклидной диагностики, Томский НИИ онкологии (г. Томск, Российская Федерация). SPIN-код: 2255-5282.

MD, PhD, radiologist, Nuclear Medicine Department, Tomsk Cancer Research Institute, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 2255-5282.

r.zelchan@yandex.ru

Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5; Национальный исследовательский Томский политехнический университет, 634009, г. Томск, пр. Ленина, 30РоссияTomsk Саnсеr Rеsеаrсh Institute, 5, Kooperativny Street, 634009-Tomsk, Russia; National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, RussiaRussian Federation

Национальный исследовательский Томский политехнический университет, 634009, г. Томск, пр. Ленина, 30РоссияNational Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, RussiaRussian Federation

2016

15072016

152101106

2016

Чернов В.И., Брагина О.Д., Синилкин И.Г., Тицкая А.А., Зельчан Р.В.

Chernov V.I., Bragina O.D., Sinilkin I.G., Titskaya A.A., Zelchan R.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/339

В обзоре литературы представлены данные, касающиеся одного из перспективных направлений таргетной терапии в современной онкологии, получившего название «радиоиммунотерапия». Особое внимание уделяется изучению возможности клинического использования данного вида системного лечения для пациентов как с онкогематологическими заболеваниями, так и с солидными опухолями.

This review presents information about one of the promising areas of targeted therapy in modern oncology, which is called radioimmunotherapy. Particular attention is paid to the possibility of clinical application of this type of systemic treatment for patients with both hematologic malignancies and solid tumors.

радиоиммунотерапиямоноклональные антителарадионуклидысолидные опухоли

radioimmunotherapymonoclonal antibodiesradionuclidessolid tumors

References1

Гервас П.А., Литвяков Н.В., Попова Н.О., Добродеев А.Ю., Тарасова А.С., Юмов Е.Л., Иванова Ф.Г., Черемисина О.В., Афанасьев С.Г., Гольдберг В.Е., Чердынцева Н.В. Проблемы и перспективы совершенствования молекулярно-генетической диагностики для назначения таргетных препаратов в онкологии // Сибирский онкологический журнал. 2014. № 2. С. 46–55.

Gervas P.A., Litviakov N.V., Popova N.O., Dobrodeev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanasyev S.G., Goldberg V.E., Cherdyntseva N.V. Problem and perspective to improve molecular testing to choose appropriate target therapy // Sibirskij onkologicheskij zhurnal. 2014. № 2. P. 46–55. [in Russian]

Имянитов Е.Н. Общие представления о таргетной терапии // Практическая онкология. 2010. Т. 11, № 3. С. 123–130.

Imyanitov E.N. General principles of targeted therapy // Practical Oncology. 2010. Vol. 11 (3). P. 123–130. [in Russian]

Моисеенко В.М. Моноклональные антитела в лечении злокачественных опухолей // Практическая онкология. 2003. Т. 4, № 3. С. 148–157.

Moiseenko V.M. Monoclononal antibody in treatment of malignancies // Practical oncology. 2003. Vol. 4 (3). P. 148–157. [in Russian]

Руководство по химиотерапии опухолевых заболеваний / Под ред. Н.И. Переводчиковой. М., 2011. 518 с.

Guidelines for chemotherapy of neoplastic diseases / Ed. by N.I. Perevodchikova. M., 2011. 518 p. [in Russian]

Практические рекомендации по лекарственному лечению злокачественных опухолей Российского общества клинической онкологии. 2014.

Practical recommendations for drug treatment of malignant tumors of the Russian Society of Clinical Oncology, 2014. [in Russian]

Клинические рекомендации. Онкология / Под ред. В.И. Чиссова, С.Л. Дарьялова. М., 2009. 925 с.

Clinical recommendation. Oncology / Ed. by V.I. Chissov, S.L. Daryalova. M., 2009. 925 p. [in Russian]

Abbas N., Heyerdahl H., Bruland O.S., Borrebæk J., Nesland J., Dahle J. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab // EJNMMI Res. 2011. Vol. 1 (1). P. 18. doi: 10.1186/2191-219X-1-18.

Akabani G., Carlin S., Welsh P., Zalutsky M.R. In vitro cytotoxicity of 211At labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction // Nucl. Med. Biol. 2006. Vol. 33 (3). P. 333–347.

Baechler S., Hobbs R.F., Jacene H.A., Bochud F.O., Wahl R.L., Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab // J. Nucl. Med. 2010. Vol. 51 (12). P. 1878–1884. doi: 10.2967/jnumed.110.079947.

Behr T.M., Liersch T., Greiner-Bechert L., Griesinger F., Béhé M., Markus P.M., Gratz S., Angerstein C., Brittinger G., Becker H., Goldenberg D.M., Becker W. Radioimmunotherapy of Small Volume Disease of Metastatic Colorectal Cancer // Cancer. 2002. Vol. 94 (4 Suppl.). P. 1373–1381.

Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Vagg R.C., Ying Z., Zhang C.H., Swayne L.C., Vardi Y., Siegel J.A., Goldenberg D.M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anticarcinoembryonic antigen murine monoclonal antibody IgG // J. Nucl. Med. 1997. Vol. 38 (6). P. 858–870.

Behr T.M., Salib A.L., Liersch T., Béhé M., Angerstein C., Blumenthal R.D., Fayyazi A., Sharkey R.M., Ringe B., Becker H., Wörmann B., Hiddemann W., Goldenberg D.M., Becker W. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study // Clin. Cancer. Res. 1999. Vol. 5 (10 Suppl.): 3232s-3242s.

Bertagnolli M.M. Radioimmunotherapy for Colorectal Cancer // Clin. Cancer. Res. 2005. Vol. 11 (13). P. 4637–4638.

Boerman O.C., Schaijk F.G., Oyen W.J., Corstens F.H. Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step // J. Nucl. Med. 2003. Vol. 44 (3). P. 400–411.

Chakraborti A.K., Garg S.K., Kumar R., Motiwala H.F., Jadhavar P.S. Progress in COX-2 inhibitors: a journey so far // Curr. Med. Chem. 2010. Vol. 17 (15). P. 1563–1593.

Chen K.T., Lee T.W., Lo J.M. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer // Nucl. Med. Biol. 2009. Vol. 36 (4). P. 355–361. doi: 10.1016/j.nucmedbio.2009.01.006.

Crow D.M., Williams L., Colcher D., Wong J.Y., Raubitschek A., Shively J.E. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti- CEA antibodies with taxol // Bioconjug. Chem. 2005. Vol. 16 (5). P. 1117–1125.

Crow D.M., Williams L., Colcher D., Wong J.Y., Raubitschek A., Shively J.E. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and antiCEA antibodies with taxol // Bioconjug. Chem. 2005. Vol. 16 (5). P. 1117–1125.

Dadachova E., Casadevall A. Radiolabeled antibodies for therapy of infectious diseases // Microbiol. Spectr. 2014. Vol. 2 (6). doi: 10.1128/microbiolspec.AID-0023-2014.

Dewaraja Y.K., Schipper M.J., Roberson P.L., Wilderman S.J., Amro H., Regan D.D., Koral K.F., Kaminski M.S., Avram A.M. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results usin g3-dimensional dosimetry including radiobiologic modeling // J. Nucl. Med. 2010. Vol. 51 (7). P. 1155–1162. doi: 10.2967/jnumed.110.075176.

Divgi C.R., Scott A.M., Dantis L., Capitelli P., Siler K., Hilton S., Finn R.D., Kemeny N., Kelsen D., Kostakoglu L., Schiom J., Larson S.M. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma // J. Nucl. Med. 1995. Vol. 36 (4). P. 586–592.

Gregory S.A., Hohloch K., Gisselbrecht C., Tobinai K., Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non Hodgkin’s lymphoma // Oncologist. 2009. Vol. 14 (Suppl 2). P. 4–16. doi: 10.1634/theoncologist.2009-S2-4.

Farrokhi S., Ravanbod M.R., Amiri S., Nabipour I., Assadi M. Radioimmunotherapy-based treatment of cancer // Iran J. Nucl. Med. 2012. Vol. 20 (1). С. 45–53.

Farrokhi S., Ravanbod M. R., Amiri S., Nabipour I., Assadi M. Radioimmunotherapy-based treatment of cancer // Iran J. Nucl. Med. 2012. Vol. 20 (1). С.45–53.

Jain M., Gupta S., Kaur S., Ponnusamy M.P., Batra S.K. Emerging Trends for Radioimmunotherapy in Solid Tumors // Cancer Biother. Radiopharm. 2013. Vol. 28 (9). P. 639–650. doi: 10.1089/cbr.2013.1523.

Hei T.K., Zhou H., Chai Y., Ponnaiya B., Ivanov V.N. Radiation induced non-targeted response: mechanism and potential clinical implications // Curr. Mol. Pharmacol. 2011. Vol. 4 (2). P. 96–105.

Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies // Scientific World Journal. 2014. P. 1–10.

Kitson S.L., Cuccurullo V., Moody T.S., Mansi L. Radionuclide antibody-conjugates, a targeted therapy towards cancer // Curr. Radiopharm. 2013. Vol. 6 (2). P. 57–71.

Kohler G., Milstein C. Continious culture of fused cells secreting antibody of predefined specificity // Nature. 1975. Vol. 256 (5517). P. 495–497.

Lane D.M., Eagle K.F., Begent R.H., Hope-Stone L.D., Green A.J., Casey J.L., Keep P.A., Kelly A.M., Ledermann J.A., Glaser M.G. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab)2 antibodies // Br. J. Cancer. 1994. Vol. 70 (3). P. 521–525.

Liersch T., Meller J., Bittrich M., Kulle B., Becker H., Goldenberg D.M. Update of carcinoembryonic antigen radioimmunotherapy with (131) I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group // Ann. Surg. Oncol. 2007. Vol. 14 (9). P. 2577–2590.

Liersch T., Meller J., Kulle B., Behr T.M., Markus P., Langer C., Ghadimi B.M., Wegener W.A., Kovacs J., Horak I.D., Becker H., Goldenberg D.M. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results // J. Clin. Oncol. 2005. Vol. 23 (27). P. 6763–6770.

Meredith R.F., Buchsbaum D.J., Alvarez R.D., LoBuglio A.F. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer // Clin. Cancer Res. 2007. Vol. 13 (18 Pt 2): 5643s–5645s.

Meredith R.F., Khazaeli M.B., Macey D.J., Grizzle W.E., Mayo M., Schlom J., Russell C.D., LoBuglio A.F. Phase II study of interferonenhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer // Clin. Cancer Res. 1999. Vol. 5 (10 Suppl): 3254s–3258s.

Murray J.L., Macey D.J., Kasi L.P., Rieger P., Cunningham J., Bhadkamkar V., Zhang H.Z., Schlom J., Rosenblum M.G., Podoloff D.A. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer // Cancer. 1994. Vol. 73 (3 Suppl). P. 1057–1066.

Nicholson S., Gooden C.S., Hird V., Maraveyas A., Mason P., Lambert H.E., Meares C.F., Epenetos A.A. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis // Oncol. Rep. 1998. Vol. 5 (1). P. 223–266.

Palm S., Back T., Claesson I., Danielsson A., Elgqvist J., Frost S., Hultborn R., Jensen H., Lindegren S., Jacobsson L. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice // Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 69 (2). P. 572–579.

Pouget J.P., Lozza1 C., Deshayes E., Boudousq V., Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy // Front. Med. (Lausanne). 2015. Vol. 2 (12). doi: 10.3389/fmed.2015.00012.

Rasaneh S., Rajabi H., Babaei M.H., Daha F.J. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer // Nucl. Med Biol. 2010. Vol. 37 (8). P. 949–955. doi: 10.1016/j.nucmedbio.2010.07.001.

Richman C.M., De Nardo S.J., O’Grady L.F., De Nardo G.L. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions // Cancer Res. 1995. Vol. 55 (23 Suppl.): 5916s–5920s.

Schrier D.M., Stemmer S.M., Johnson T., Kasliwal R., Lear J., Matthes S., Taffs S., Dufton C., Glenn S.D., Butchko G., Ceriani R., Rovira D., Bunn P., Shpall E.J., Bearman S.I., Purdy M., Cagnoni P., Jones R.B. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial // Cancer Res. 1995. Vol. 55 (23 Suppl.). P. 5921s–5924s.

Pandit-Taskar N., Jhaveri K., Divgi C. Radioimmunotherapy (RIT) of Cancer // Indian Journal of Nuclear Medicine. 2004. Vol. 19 (3). P. 53–67.

Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer Biochemical et Biophysical Acta (BBA) // Molecular Basis of Disease. 1999. Vol. 1455 (2–3). P. 301–313.

Tempero M., Leichner P., Baranowska-Kortylewicz J., Harrison K., Augustine S., Schlom J., Anderson J., Wisecarver J., Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial // Clin. Cancer Res. 2000. Vol. 6 (8). P. 3095–3102.

Tomblyn M.B., Katin M.J., Wallner P.E. The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymore // Cancer Control. 2013. Vol. 20 (1). P. 60–71.

Wheeler R.H., Meredith R.F., Saleh M.N. A phase II trial of IL-1+ radioimmunotherapy (RIT) in patients with metastatic colon cancer // J. Clin. Oncol. 1994. Vol. 13. Abstract 959.

Schaefer N.G., Huang P., Buchanan J.W., Wahl R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists // J. Nucl. Med. 2011. Vol. 52 (5). P. 830–838. doi: 10.2967/jnumed.110.085589.

Wang C.K. The progress of radiobiological models in modern radiotherapy with emphasis on the uncertain tissue // Mutat. Res. 2010. Vol. 704 (1–3). P. 175–181. doi: 10.1016/j.mrrev.2010.02.001

Wang C.K. The progress of radiobiological models in modern radiotherapy with emphasis on the uncertain tissue // Mutat. Res. 2010. Vol. 704 (1–3). P. 175–181. doi: 10.1016/j.mrrev.2010.02.001.

The authors declare that there are no conflicts of interest present.